Isolated Diplopia as an Initial Indicator of Fulminant Myocarditis
Overview
This report details a rare case of fulminant myocarditis associated with undifferentiated connective tissue disease, initially presenting as isolated diplopia. The patient experienced significant clinical improvement following appropriate immunosuppressive therapy after a complex diagnostic journey.
Background
Undifferentiated connective tissue disease (UCTD) can lead to severe complications such as fulminant myocarditis, which is often underrecognized due to overlapping symptoms with other cardiac conditions. Early diagnosis and treatment are crucial to prevent potentially fatal outcomes. This case emphasizes the importance of considering atypical presentations in the diagnosis of autoimmune myocarditis.
Data Highlights
No numerical data available in the article.
Key Findings
Isolated diplopia can be a rare initial manifestation of UCTD-associated fulminant myocarditis.
The patient had elevated cardiac enzymes and ECG changes suggestive of myocardial infarction, but coronary angiography showed no stenosis.
Premature tapering of corticosteroids led to relapse, highlighting the need for careful management of immunosuppressive therapy.
At three-year follow-up, the patient remained in remission with complete resolution of symptoms.
Clinical Implications
Clinicians should be aware of atypical presentations of myocarditis, such as isolated diplopia, particularly in patients with UCTD. Endomyocardial biopsy is essential for accurate diagnosis and treatment guidance. Careful management of corticosteroid therapy is critical to prevent relapse.
Conclusion
This case underscores the diagnostic challenges of autoimmune myocarditis and the necessity for vigilant monitoring and tailored treatment strategies in patients with UCTD.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
